D359-0396

• Description :

  D359-0396 is an orally active NLRP3 inflammasome inhibitor. D359-0396 inhibits pyroptosis and IL-1β release in macrophages. D359-0396 also inhibits the oligomerization of NLRP3, ASC and the cleavage of GSDMD. D359-0396 alleviates EAE, and also improves survival after septic shock in mice[1].

• UNSPSC :

  12352005

• Target :

  NOD-like Receptor (NLR) ; Pyroptosis

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/d359-0396.html

• Purity :

  99.98

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1C2=CN3C4=C(NC(C3=C2N(C)C(N1C)=O)C5=CC=C(C(C)C)C=C5)C=CC=C4

• Molecular Formula :

  C24H24N4O2

• Molecular Weight :

  400.47

• References & Citations :

  [1]Li Z, et al. Identification of D359-0396 as a novel inhibitor of the activation of NLRP3 inflammasome. Neurochem Int. 2023 Oct;169:105565.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1031977-31-7]